Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
MIST Stock Chart & Stats
$1.70
-$0.02(-0.90%)
At close: 4:00 PM EST
$1.70
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$0.63 - $3.06
Previous CloseN/A
Volume143.50K
Average Volume (3M)1.34M
Market Cap
$115.83M
Enterprise Value$101.16M
Total Cash (Recent Filing)$105.96M
Total Debt (Recent Filing)$58.38M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
May 18, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding85,169,340
10 Day Avg. Volume1,370,248
30 Day Avg. Volume1,337,367
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.46
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue70.45
Enterprise Value/Gross Profit-1.26K
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$8.00Price Target Upside370.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$37.94M
Bulls Say, Bears Say
Bulls Say
Commercial TractionInitial launch metrics show prescriptions are being written and a sales force of 60 representatives is engaging targeted prescribers, indicating the product is reaching patients and demand is developing despite limited payer access.
Regulatory Progress In EuropeThe European Medicines Agency's acceptance of the marketing application advances the nasal spray toward potential EU approval, creating the possibility of new commercial markets and partner opportunities.
Unrecognized European And Indication UpsideAnalyst's valuation model excludes any value for the European opportunity and potential atrial fibrillation development, so EU approval or label expansion could provide incremental upside beyond current forecasts.
Bears Say
Intellectual Property And Funding RiskIntellectual property uncertainty and the potential need for additional funding if revenue falls short may dilute shareholders or slow commercialization progress.
Regulatory And Indication RiskRegulatory hurdles for new indications such as atrial fibrillation could delay or block label expansion and limit the addressable market for the nasal spray.
Reimbursement BottleneckLack of contracted payer coverage is creating prior authorization hurdles and payer controls that can delay or prevent prescriptions from being filled, constraining revenue realization.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $0.63 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $115.83M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 56 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Mar 20, 2026. The company reported -$0.16 earnings per share for the quarter, the consensus estimate of -$0.16 by $0.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is 0.1.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 85,169,340 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, expectations of -$0.16. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (370.59% Upside)
$8.00 (370.59% Upside)
Blogger Sentiment
Bullish
MIST Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.25%
12-Months-Change
Fundamentals
Return on Equity
-826.79%
Trailing 12-Months
Asset Growth
50.41%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
MIST Earnings Call
Q4 2026
0:00 / 0:00
MIST Stock 12 Month Forecast
Average Price Target
$8.00
▲(370.59% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
1.36% Insiders
0.09% Mutual Funds
16.54% Other Institutional Investors
80.19% Public Companies and
Individual Investors